Oncology

BMS combo would gain heft in melanoma space, say analysts

BMS combo would gain heft in melanoma space, say analysts

By

The promise of an Opdivo/Yervoy combination, now awaiting FDA approval, has more to do with payer strategy than efficacy, analysts say.

Five things for pharma marketers to know: Friday, June 19

Five things for pharma marketers to know: Friday, June 19

Teva loses Copaxone patent suit; Oncologists at Memorial Sloan Kettering Cancer Center developed cancer drug cost calculator; Bayer will invest $4.5 billion in R&D in the coming year.

Lilly moves to bolster its oncology pipeline

Harvard's Dana-Farber Cancer Institute and the Sarah Cannon Research Institute signed on to help the drugmaker develop cancer treatments.

Study: 10 medications will cost US $50 billion over 10 years

Study: 10 medications will cost US $50 billion over 10 years

By

An analysis by Avalere Health says 10 breakthrough therapy drugs will account for billions in spending.

Genentech game invites players to attack cancer

The first of seven games aimed at teaching about immuno-oncology lets players fling antibodies at cancer cells.

Five things for pharma marketers to know: Monday, June 1

Five things for pharma marketers to know: Monday, June 1

By

Bristol-Myers Squibb's Opdivo serves up lukewarm lung-cancer results; new cancer drugs are too expensive, Sloan Kettering oncologist tells ASCO attendees; Teva settlement could stymie industry use of pay-for-delay patent tactics

Express Scripts wants cancer drugs to prove value

Express Scripts wants cancer drugs to prove value

By

The pharmacy benefits manager wants oncology treatments priced according to how well they treat a specific cancer as opposed to using the current one-price-fits-all approach.

Roche diagnostic unit partnering with drugmaker on companion diagnostic

The test seeks to identify patients with metastatic pancreatic cancer and high levels of hyaluronan.

Five things for pharma marketers to know: Wednesday, May 27

Five things for pharma marketers to know: Wednesday, May 27

By

Express Scripts seeks to pay more for top-performing cancer drugs; Olympus plans to settle marketing investigation; Novartis is collaborating on a robotic pill

ASCO preview: What's coming for lung cancer

ASCO preview: What's coming for lung cancer

By

A horse race between Merck and Bristol-Myers Squibb, and the importance of one biomarker, will be a focus at the American Society of Clinical Oncology's annual meeting.

Five things for pharma marketers to know: Thursday, May 21

Five things for pharma marketers to know: Thursday, May 21

By

CVS will buy institutional pharmacy Omnicare in a $12.7-billion deal; ProPublica says the FDA and GlaxoSmithKline failed to protect patients from misusing Advair; Regeneron and Sanofi expect to file RA drug sarilumab with the FDA in the fourth quarter of this year

Cancer center and tech co. test Apple Watch in breast-cancer patients

Cancer center and tech co. test Apple Watch in breast-cancer patients

By

Parties in the effort say the novelty of wearing an Apple Watch, along with a newly developed app, may help clinicians refine treatment plans and patient support.

Five things for pharma marketers to know: Tuesday, May 19

Five things for pharma marketers to know: Tuesday, May 19

By

Perrigo says a Mylan deal is possible; new guidelines may reduce cancer screenings; Takeda petitions dictionaries to add a new definition for depression

Study: Diagnostics not keeping pace with personalized medicine

Study: Diagnostics not keeping pace with personalized medicine

By

Precision medicine is a guiding force for many pipelines, but a study shows a gap between developing drugs with biomarkers as well as tests that match patients to treatments.

Five things for pharma marketers to know: Thursday, May 14

Five things for pharma marketers to know: Thursday, May 14

By

An economist wants $37 billion invested in antibiotic development; Roche plans to file an experimental lung-cancer drug with the FDA this year; Sandoz wants compensation for lost Zarxio sales

Five things for pharma marketers to know: Tuesday, May 12

Five things for pharma marketers to know: Tuesday, May 12

By

Mylan considers higher bid for Perrigo; Boehringer Ingelheim partners with health system on COPD; EMD Serono's experimental cancer drug gets Fast Track status

AbbVie leukemia drug gets breakthrough status

AbbVie expected to submit chronic lymphocytic leukemia drug venetoclax to the FDA this year.

Myriad expands companion diagnostic deals

Myriad expands companion diagnostic deals

By

The company partnered with AstraZeneca and BioMarin to identify which patients respond to experimental cancer drugs.

Five things for pharma marketers to know: Tuesday, May 5

Five things for pharma marketers to know: Tuesday, May 5

By

Worldwide spending on cancer medications hit $100 billion last year; Bayer adds an anticoagulant to its pipeline for $100 million; GlaxoSmithKline has a new chairman

Drugmakers will have to show more than efficacy to justify price

Drugmakers will have to show more than efficacy to justify price

By

The IMS Institute for Healthcare Informatics says makers of cancer drugs will need more than data points for payers to see the value in their pricey new treatments.

Five things for pharma marketers to know: Thursday, April 30

Five things for pharma marketers to know: Thursday, April 30

By

FDA advisory panel recommends Amgen's T-Vec; Teva again makes the case for a merger with Mylan; the FDA approves injection to treat double chins

Bristol-Myers Squibb sales rise, led by Eliquis and Opdivo

Bristol-Myers Squibb sales rise, led by Eliquis and Opdivo

By

Newly approved Opdivo added $40 million to the quarter's product sales, which rose 8.9% compared to the year-earlier period.

Pfizer reports uptake for cancer-therapy Ibrance

Pfizer reports uptake for cancer-therapy Ibrance

By

Sales of the new cancer drug topped expectations since its February launch.

FDA says Amgen cancer data can't support accelerated approval

FDA says Amgen cancer data can't support accelerated approval

By

Briefing materials released before Wednesday's panel review indicate the regulator wants clearer data to assess Amgen's experimental melanoma treatment.

Five things for pharma marketers to know: Monday, April 27

Five things for pharma marketers to know: Monday, April 27

By

More pharma companies hike drug prices post-acquisition; HCV linked to increased risk of cancer; a combined Teva-Mylan would control 25% of the US generic drug market

Five things for pharma marketers to know: Friday, April 24

Five things for pharma marketers to know: Friday, April 24

By

An AbbVie hep.-C drug nabbed priority review; Merck's hep.-C drug matches efficacy of Harvoni; Mylan increased its bid to buy Perrigo

Lilly sees sales fall but reaffirms 2015 revenue guidance

Lilly sees sales fall but reaffirms 2015 revenue guidance

By

First-quarter sales fell 1% but the drugmaker expects 2015 to be a growth year.

Five things for pharma marketers to know: Wednesday, April 22

Five things for pharma marketers to know: Wednesday, April 22

By

Study finds vaccines still not linked to autism; investments in healthcare start-ups hit record high this year; biosimilars are already bearing down on prices overseas

Merck files Keytruda for lung cancer, eyes first-line niche

Merck files Keytruda for lung cancer, eyes first-line niche

By

Genetic protein PD-L1 could have potential as a biomarker for a first-line treatment.

Five things for pharma marketers to know: Monday, April 20

Five things for pharma marketers to know: Monday, April 20

By

Teva eyes Mylan takeover; Keytruda shown to improve survival, shrink tumors in melanoma; ADHD abuse may follow grads into workforce.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.